Kyowa Kirin International plc
At Kyowa Kirin International plc “Commitment to Life” is at our core. With over 500 people focused on this purpose we’ve become a highly successful and rapidly growing specialty pharmaceutical company engaged in the development and commercialization of innovative medicines for the treatment of unmet therapeutic needs in major western markets. Kyowa Kirin International plc is owned by Kyowa Hakko Kirin Co., Ltd (KHK) of Japan. Founded in 1949, KHK has a successful track record in Japan and is now expanding globally. Our highly successful product portfolio, enviable pipeline and active Business Development group provides a wealth of products in the therapeutic areas of Oncology, CNS and Nephrology. With three key anti-body therapies in late stage development Kyowa Kirin is setting the scene for transformative growth.